Renaissance Capital IPO Center
Syndax Pharmaceuticals, a late-stage biotech developing a novel therapy for treatment-resistant breast cancer, refiled on Monday with the SEC to raise up to $86 million in an initial public offering.
The company originally set terms in June 2014 to raise $60 million, but withdrew its offering.
The Waltham, MA-based company was founded in 2005 and plans to list on the Nasdaq under the symbol SNDX. Syndax Pharmaceuticals filed confidentially on August 25, 2015. Morgan Stanley and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.
20 September 2017
19 September 2017